Literature DB >> 6824588

Immune disorders in agnogenic myeloid metaplasia: relations to myelofibrosis.

E Rondeau, P Solal-Celigny, D Dhermy, M Vroclans, N Brousse, J F Bernard, P Boivin.   

Abstract

Tests for a dysimmune state were done in an unselected group of 67 patients with agnogenic myeloid metaplasia (AMM). The results were compared to those of 56 patients with polycythaemia vera (PV). 75% of AMM patients versus 32% of PV patients had various abnormalities. The most frequent disorders among AMM patients were serum antinuclear and anti smooth muscle autoantibodies (10.3% each), a positive test for rheumatoid factor (21.7%), a polyclonal increase in serum immunoglobulin levels (46.8%) or a serum monoclonal component (9.7%), a positive direct Coombs' test (19%), an anti I autoantibody (30%). In AMM patients there was no relationship between age, sex, importance of splenic enlargement, time from diagnosis or treatment and the present of a dysimmunity. Furthermore, in AMM patients, but also in PV patients, it seems that the more frequent and numerous these abnormalities the more severe is the myelofibrosis. Like other previous studies, these results suggest a lymphoid cell involvement in AMM and a role for these immune disorders in the pathogenesis of myelofibrosis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6824588     DOI: 10.1111/j.1365-2141.1983.tb02048.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

Review 1.  Pathogenesis of idiopathic myelofibrosis: role of growth factors.

Authors:  J T Reilly
Journal:  J Clin Pathol       Date:  1992-06       Impact factor: 3.411

2.  Inherited predisposition to myeloproliferative neoplasms.

Authors:  Amy V Jones; Nicholas C P Cross
Journal:  Ther Adv Hematol       Date:  2013-08

3.  Hepatic and portal vein-thrombosis.

Authors:  B J Boughton
Journal:  BMJ       Date:  1991-01-26

4.  Monoclonal gammopathy in chronic myeloproliferative disorders.

Authors:  T Economopoulos; J Economidou; E Papageorgiou; J Dervenoulas; C Christodoulides; V Pappa; D Karakassis; C Terzoglou; S Athanassiadou; G Chalevelakis
Journal:  Blut       Date:  1989-01

5.  Circulating high molecular weight IgG fibronectin complexes in myeloproliferative disorders.

Authors:  T P Baglin; S M Price; B J Boughton
Journal:  J Clin Pathol       Date:  1990-02       Impact factor: 3.411

6.  Histomorphometry of bone marrow biopsies in primary osteomyelofibrosis/-sclerosis (agnogenic myeloid metaplasia)--correlations between clinical and morphological features.

Authors:  J Thiele; B Hoeppner; R Zankovich; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

7.  Frequent association of idiopathic myelofibrosis with plasma cell dyscrasias.

Authors:  U Dührsen; M Uppenkamp; P Meusers; E König; G Brittinger
Journal:  Blut       Date:  1988-03

Review 8.  An immune dysregulation in MPN.

Authors:  Giovanni Barosi
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

9.  Immunohistochemical evaluation of bone marrow lymphoid nodules in chronic myeloproliferative disorders.

Authors:  V Franco; A M Florena; F Aragona; G Campesi
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

10.  PRCA with myelofibrosis: an unusual case report.

Authors:  Rakhee Kar; Manoranjan Mahapatra; Hara P Pati
Journal:  Indian J Hematol Blood Transfus       Date:  2008-05-01       Impact factor: 0.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.